Roche/Abbvie's Venclexta Outshines Agios IDH Inhibition In AML At ASH
Executive Summary
Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
AbbVie's Rova-T Disappoints As Second-Line SCLC Trial Halted
Enrolment In the Phase III TAHOE study has been halted due to shorter overall survival in the Rova-T arm compared with the control arm.
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.